ERBB2 and breast carcinoma: In this study, we identified tGLI1 and IL-6/IL-6R/GP130 signaling pathways to be frequently co-overexpressed, co-activated, and functionally cooperate to promote breast CSCs in HER2-enriched breast cancer and TNBC.